Big pharma company GSK - a British company based in, under the jurisdiction, and listed on the stock market of the UK - becomes the first British company I’ve noticed that is using the election of a foreign leader, Donald Trump, and his ridiculous preferences and policies as an excuse to ‘pause’ their own diversity, equity and inclusion programs.
References to “diversity, equity and inclusion”, present as late as 19 February according to the Internet Archive, were changed to merely “inclusion” on one section of GSK’s website.
Mentoring groups for women have been put on hold, as has a social mobility programme in the UK that works with students from less-privileged socioeconomic groups to support them entering the workplace, according to sources. Charitable activities with a diversity element are also under review.
Presumably this is entirely unrelated to the issue of money, given they’re currently considering raising the annual salary of their Chief Executive from around £11 million to £22 million on the basis that the former is “insufficient either to reward her performance, or to provide the appropriate capacity for succession”.